U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281586) titled 'Step-down Therapy After Long-term Osteoporosis Treatment' on Nov. 25.
Brief Summary: Maintaining bone mineral density (BMD) after discontinuing denosumab (Prolia) is a major clinical challenge, as rapid bone loss commonly occurs when treatment is stopped, especially after more than three years of use. Standard sequential therapy with bisphosphonates such as zoledronic acid (Aclasta) often fails to fully prevent BMD decline, and most bone loss occurs within the first year, making effective suppression of the rebound effect essential.
This study investigates whether a de-escalation strategy-using half-dose denosumab (30 mg every six ...